Adagene Inc. is a clinical-stage biotechnology company focused on developing monoclonal antibody therapeutics for cancer treatment, primarily serving markets in China. The company's pipeline centers on immuno-oncology candidates, including ADG126, a masked fully-human anti-CTLA-4 antibody in phase 1b/2 development, and ADG116, another anti-CTLA-4 candidate also in phase 1b/2 trials. Additional programs in clinical development include ADG104 (anti-PD-L1, phase 2), ADG206 (phase 1), and ADG125 (anti-CSF-1R, phase 2).
Beyond its clinical-stage assets, Adagene is advancing several preclinical candidates utilizing proprietary platforms. These include bispecific antibodies designated as POWERbody and SAFEbody formats, such as ADG138 (HER2xCD3), ADG152 (CD20xCD3), and ADG153 (masked anti-CD47). The company is also developing CD28 T-cell engagers targeting solid tumors.
Adagene was incorporated in 2011 and maintains headquarters in Suzhou, China. The company operates with approximately 138 full-time employees and is listed on Nasdaq. As a clinical-stage entity, the company has not generated meaningful revenue from product commercialization.
No 10-K filings found.